TG Therapeutics (TGTX) Competitors $37.08 -0.59 (-1.57%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$37.16 +0.08 (+0.22%) As of 07/11/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX vs. TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, MRNA, ASND, and VTRSShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. Its Competitors Teva Pharmaceutical Industries Insmed Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris TG Therapeutics (NASDAQ:TGTX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Which has preferable earnings and valuation, TGTX or TEVA? TG Therapeutics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$386.39M15.24$23.38M$0.24154.50Teva Pharmaceutical Industries$16.54B1.14-$1.64B-$1.15-14.25 Do institutionals & insiders hold more shares of TGTX or TEVA? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor TGTX or TEVA? In the previous week, TG Therapeutics had 3 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 14 mentions for TG Therapeutics and 11 mentions for Teva Pharmaceutical Industries. TG Therapeutics' average media sentiment score of 1.28 beat Teva Pharmaceutical Industries' score of 0.71 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TGTX or TEVA? TG Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Is TGTX or TEVA more profitable? TG Therapeutics has a net margin of 10.13% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics10.13% 18.88% 7.05% Teva Pharmaceutical Industries -7.74%45.44%6.95% Do analysts recommend TGTX or TEVA? TG Therapeutics presently has a consensus target price of $43.80, suggesting a potential upside of 18.12%. Teva Pharmaceutical Industries has a consensus target price of $24.71, suggesting a potential upside of 50.79%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryTG Therapeutics beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks. Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.89B$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio154.5020.8528.2620.26Price / Sales15.24303.05437.10166.10Price / Cash309.1442.1137.1257.67Price / Book25.937.638.045.49Net Income$23.38M-$55.05M$3.19B$250.45M7 Day Performance-0.32%8.43%3.62%4.79%1 Month Performance2.97%8.14%5.98%9.59%1 Year Performance74.99%1.62%29.39%16.41% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics3.6936 of 5 stars$37.08-1.6%$43.80+18.1%+75.0%$5.89B$386.39M154.50290News CoveragePositive NewsAnalyst UpgradeTEVATeva Pharmaceutical Industries4.1226 of 5 stars$16.76flat$24.13+43.9%-5.2%$19.22B$16.54B-14.5736,800INSMInsmed4.3703 of 5 stars$100.64+1.2%$106.80+6.1%+28.0%$19.09B$363.71M-16.91740Positive NewsAnalyst ForecastInsider TradeSMMTSummit Therapeutics2.8485 of 5 stars$21.28+3.3%$35.09+64.9%+192.4%$15.80B$700K-62.59110ITCIIntra-Cellular Therapies0.6591 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0955 of 5 stars$20.66+0.8%$37.60+82.0%-20.9%$13.25B$3.12B11.742,682Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.7627 of 5 stars$15.03-0.3%$16.95+12.8%-8.8%$12.55B$3.81B22.7727,811QGENQiagen3.5759 of 5 stars$48.07+0.6%$49.40+2.8%+17.4%$10.69B$1.98B120.525,765MRNAModerna4.3037 of 5 stars$27.59+1.6%$46.61+68.9%-72.3%$10.67B$3.24B-3.165,800Trending NewsASNDAscendis Pharma A/S3.6014 of 5 stars$172.60+0.2%$220.67+27.8%+26.7%$10.55B$393.54M-27.481,017News CoverageAnalyst ForecastVTRSViatris2.9038 of 5 stars$8.93-0.9%$10.40+16.5%-18.9%$10.48B$14.74B-2.8232,000 Related Companies and Tools Related Companies Teva Pharmaceutical Industries Alternatives Insmed Alternatives Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives Moderna Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TGTX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
